|
Basic Characteristics of Mutations
|
|
Mutation Site
|
A879S |
|
Mutation Site Sentence
|
TABLE |
|
Mutation Level
|
Amino acid level |
|
Mutation Type
|
Nonsynonymous substitution |
|
Gene/Protein/Region
|
S |
|
Standardized Encoding Gene
|
S
|
|
Genotype/Subtype
|
- |
|
Viral Reference
|
NC_045512;MN908947.3
|
|
Functional Impact and Mechanisms
|
|
Disease
|
-
|
|
Immune
|
Y |
|
Target Gene
|
-
|
|
Clinical and Epidemiological Correlations
|
|
Clinical Information
|
Y |
|
Treatment
|
- |
|
Location
|
- |
|
Literature Information
|
|
PMID
|
35538074
|
|
Title
|
Cumulative SARS-CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral evolution within the host
|
|
Author
|
Sonnleitner ST,Prelog M,Sonnleitner S,Hinterbichler E,Halbfurter H,Kopecky DBC,Almanzar G,Koblmuller S,Sturmbauer C,Feist L,Horres R,Posch W,Walder G
|
|
Journal
|
Nature communications
|
|
Journal Info
|
2022 May 10;13(1):2560
|
|
Abstract
|
Different scenarios explaining the emergence of novel variants of concern (VOC) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been reported, including their evolution in scarcely monitored populations, in animals as alternative hosts, or in immunocompromised individuals. Here we report SARS-CoV-2 immune escape mutations over a period of seven months in an immunocompromised patient with prolonged viral shedding. Signs of infection, viral shedding and mutation events are periodically analyzed using RT-PCR and next-generation sequencing based on naso-pharyngeal swabs, with the results complemented by immunological diagnostics to determine humoral and T cell immune responses. Throughout the infection course, 17 non-synonymous intra-host mutations are noted, with 15 (88.2%) having been previously described as prominent immune escape mutations (S:E484K, S:D950N, S:P681H, S:N501Y, S:del(9), N:S235F and S:H655Y) in VOCs. The high frequency of these non-synonymous mutations is consistent with multiple events of convergent evolution. Thus, our results suggest that specific mutations in the SARS-CoV-2 genome may represent positions with a fitness advantage, and may serve as targets in future vaccine and therapeutics development for COVID-19.
|
|
Sequence Data
|
-
|
|
|